Skip to content
Kendall Square
Getting Around
Kendall’s History
Events & Culture
Kendall Map
Kendall Square Association
About
Membership
KSA Events
KSA Programs
Strategic Initiatives
Government Relations
Board
Team
In the Media
Menu
Events & Culture
Transportation
DEI - Inclusion Drives Innovation
Work Now Task Force
Kendall Collaborations
About
Join KSA
Announcements
Biogen completes the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer’s disease.
Jul 09, 2020
Share
Share on Twitter
Share on Facebook
Close
Previous
←
Next
→
/